Shitara N, Nakamura H, Genka S, Takakura K
Dept. of Neurosurgery, University of Tokyo.
Gan To Kagaku Ryoho. 1987 Dec;14(12):3235-44.
The role of Interferon-beta (IFN-beta) as maintenance therapy for malignant gliomas and medulloblastomas was described. The low dose but continuous long-term administration of IFN-beta as a maintenance treatment for malignant gliomas after the induction therapy with surgery and chemoradiotherapy demonstrated the complete remission of the tumor in six cases of malignant gliomas. Such method of IFN-beta administration did not induce any serious side effects and might be useful for treatment of malignant gliomas. In addition, recent advance of adoptive immunotherapy using lymphokine activated killer cells (LAK) was briefly reviewed.
描述了β-干扰素（IFN-β）作为恶性胶质瘤和髓母细胞瘤维持治疗的作用。在手术及放化疗诱导治疗后，低剂量但持续长期给予IFN-β作为恶性胶质瘤的维持治疗，在6例恶性胶质瘤患者中实现了肿瘤完全缓解。这种IFN-β给药方法未引起任何严重副作用，可能对恶性胶质瘤治疗有用。此外，还简要回顾了使用淋巴因子激活杀伤细胞（LAK）的过继性免疫治疗的最新进展。
